Table 1.
The PI3K/Akt signaling in prostate cancer progression
| Signaling networks | Remarks | Refs |
|---|---|---|
| CCR9/CCL25/PI3K/Akt |
CCR9 binds to CCL25 to induce PI3K/Akt signaling Apoptosis inhibition Reducing anti-cancer activity of etoposide |
(Sharma et al. 2010) |
| EpCAM/PI3K/Akt/mTOR |
Association with prostate cancer metastasis Mediating drug resistance and radio-resistance EpCAM induces PI3K/Akt signaling |
(Ni et al. 2013) |
| PTEN/PI3K/Akt | PTEN suppresses PI3K/Akt signaling to promote cell death caused by cetuximab | (Bouali et al. 2009) |
| PI3K/Akt/GR | Inhibition of PI3K/Akt signaling reduces GR expression in reversing enzalutamide resistance in prostate cancer | (Adelaiye-Ogala et al. 2020) |
| PI3K/Akt | A combination of docetaxel and thymoquinone can stimulate apoptosis in prostate cancer via inhibition of PI3K/Akt signaling | (Singh et al. 2019) |
| ROS/PI3K/Akt/mTOR | Arctigenin promotes ROS generation to suppress PI3K/Akt/mTOR axis in inducing mitochondrial dysfunction and impairing tumor progression | (Lee et al. 2018) |
| PI3K/C2β | Inhibition of PI3K/C2β reduces cell division in prostate cancer and increases docetaxel sensitivity of tumor cells | (Cisse et al. 2019) |
| INNP4B/PI3K/Akt | INPP4B suppresses PI3K/Akt signaling in inhibiting docetaxel resistance | (Chen et al. 2016) |
| PI3K/Akt/mTOR | Radiation induces autophagy and promotes drug sensitivity via suppressing PI3K/Akt/mTOR axis | (Wu et al. 2018a, b) |
|
PI3K/mTOR PIM |
Co-inhibition of PI3K/mTOR and PIM is promising in suppressing prostate cancer progression | (Luszczak et al. 2020) |
| PI3K/Akt/NF-κB | Apigenin suppresses PI3K/Akt axis to reduce NF-κB expression in impairing prostate cancer progression | (Erdogan et al. 2016) |
| PI3K/Akt/mTOR | Rottlerin stimulates apoptosis and autophagy in prostate tumor cells | (Kumar et al. 2014) |
|
PI3K/Akt MAPK |
Overexpression of PI3K/Akt and MAPK stimulates drug resistance in prostate cancer | (Liu et al. 2015) |
| Midkine/PI3K/Akt | Down-regulation of midkine suppresses PI3K/Akt signaling and promotes efficacy of quercetin in prostate tumor inhibition | (Erdogan et al. 2018) |
| SOX2/PI3K/Akt | SOX2 stimulates PI3K/Akt signaling in mediating paclitaxel resistance in prostate cancer | (Li et al. 2014) |
| CNTN-1/PI3K/Akt | CNTN-1 induces EMT and PI3K/Akt signaling to mediate docetaxel resistance in prostate cancer | (Chen et al. 2021a, b) |
| PI3K/Akt | Quercetin promotes docetaxel sensitivity of prostate tumor cells via PI3K/Akt inhibition | (Lu et al. 2020) |
| miRNA-4638-5p/PI3K/Akt | miRNA-4638-5p prevents development of castration resistance in prostate cancer via suppressing PI3K/Akt signaling | (Wang et al. 2016) |
| SPP1/PI3K/Akt | SPP1 induces PI3K/Akt signaling to mediate EMT and enzalutamide resistance in prostate cancer | (Pang et al. 2021) |
| CamKII/Akt/mTOR | Citrate suppresses CamKII/Akt/mTOR axis in inducing autophagic cell death in prostate tumor | (Fan et al. 2021) |
| miRNA-1297/PTEN/Akt/ERK | miRNA-1297 induces Akt/ERK axis via PTEN down-regulation to increase proliferation and metastasis of prostate tumor cells | (Wang et al. 2021a, b, c, d, e, f) |
| Akt | Solamargine inhibits proliferation of prostate tumor cells and enhances docetaxel sensitivity via Akt signaling inhibition | (Ge et al. 2022) |
| LIFR/PDPK1/Akt/GCN5 | LIFR induces Akt signaling and related molecular pathways in increasing progression of prostate tumor cells | (Ding et al. 2022) |
| FBXO31/DUSP6/PI3K/Akt | FBXO31 down-regulation in prostate cancer promotes DUSP6 expression to induce PI3K/Akt signaling in promoting tumor formation | (Duan et al. 2021) |
| CMTM5/EGFR/PI3K/Akt | CMTM5 inhibits PI3K/Akt signaling via EGFR down-regulation to decrease proliferation and colony formation in prostate tumor | (Li et al. 2022a, b) |
| miRNA-130b/PI3K/Akt | miRNA-130b as tumor-suppressor factor, suppresses PI3K/Akt signaling in reducing metastasis of prostate cancer cells | (Jia et al. 2022) |
| - | Inhibiting PI3K p110β prevents development of castration resistance in prostate cancer | (Gao et al. 2022) |
| PLK4/PI3K/Akt | Fraxetin inhibits PI3K/Akt signaling via PLK4 down-regulation to impair growth and metastasis of prostate tumor cells | (Ma et al. 2022) |
| miRNA-192-5p/PI3K/CHOP | BK002 as anti-cancer agent, promotes miRNA-192-5p expression to inhibit PI3K signaling, leading to CHOP overexpression and apoptosis induction in prostate tumor cells | (Park et al. 2022) |
| KDM5A/miRNA-330-3p/PI3K/Akt | KDM5A reduces miRNA-330-3p expression to induce PI3K/Akt signaling in increasing prostate cancer tumorigenesis | (Mi et al. 2022) |